الصفحة الرئيسية>>AD 01

AD 01

رقم الكتالوجGC50581

AD 01 ، 24 ببتيد من الأحماض الأمينية من FKBPL (مثل بروتين رابط FK506) ، يمتلك نشاطًا قويًا مضادًا لتولد الأوعيةيرتبط AD 01 بمستقبل CD44 ويمنع هجرة الخلايا السرطانية بطريقة تعتمد على CD44

Products are for research use only. Not for human use. We do not sell to patients.

AD 01 التركيب الكيميائي

Cas No.: 959961-23-0

الحجم السعر المخزون الكميّة
1mg
315٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

FKBPL (FK506-binding protein like)-based peptide. Binds to and upregulates expression of CD44. Inhibits breast cancer stem cell (BCSC) growth. Decreases pluripotency markers and promotes differentiation of BCSCs. Also inhibits endothelial cell migration as well as tubule and microvessel formation in vitro and in vivo. Blocks tumor growth in xenograft models.

Yakkundi et al (2013) The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway. PLoS One. 8 e55075 PMID:23457460 |McClements et al (2013) Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway. Clin.Cancer Res. 19 3881 PMID:23741069 |Valentine et al (2011) FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism. Clin.Cancer Res 17 1044 PMID:21364036

مراجعات

Review for AD 01

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AD 01

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.